Related Experiment Video

Updated: Mar 30, 2026

qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

Published on: March 6, 2019

[Association between polymorphisms of killer cell immunoglobulin-like receptor gene and the risk of essential

Xun Zhou¹, Yonghong Zhang², Bo Jiang³

¹Department of Epidemiology, School of Public Health, Medical College of Soochow University; Grade 2012, Five-Year Program Clinic Medicine, Medical College of Soochow University, Suzhou 215123, China.

Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi

|November 14, 2015

Abstract

Objective:

To assess the association between killer cell immunoglobulin-like receptor (KIR) gene polymorphisms and the risk of hypertension in autoimmune mechanism.

Methods:

We conducted a case-control study including 205 hypertensives and 205 controls matched with sex and age, from a community-based population. KIR genes of all subjects were genotyped by polymerase chain reaction with sequence-specific primers (PCR-SSP). Conditional logistic regression model and generalized multifactor dimensionality reduction (GMDR) method were used to estimate the association among KIR gene polymorphisms and the risk of hypertension.

Results:

The genotypic frequencies of KIRs were not significantly different between the hypertensives and the control groups (P > 0.05). Among all the models of GMDR concerning the association between interactions of KIR genes and essential hypertension, the testing accuracy of the interaction between KIR2DS2 and KIR2DS3 was the highest (55.13%), with cross-validation consistency as 10/10 (P = 0.054). Results from the conditional logistic regression showed that individuals with KIR2DS2+: KIR2DS3- were significantly associated with an increased risk on hypertension (OR = 2.555, 95% CI: 1.203-5.429, P = 0.015). However, individuals with KIR2DS2+: KIR2DS3+ were significantly associated with a reduced risk of hypertension (OR = 0.268, 95% CI: 0.088-0.815, P = 0.020). Individuals with KIR2DS2- KIR2DS3+ did not seem to be associated with the risk of hypertension (OR = 1.602, 95% CI: 0.785-3.266, P = 0.195), when compared to the KIR2DS2- KIR2DS3- group. Interactions between KIR2DS2 and KIR2DS3 were significantly associated with the risk of hypertension, after adjusted for BMI, smoking, drinking and family history of hypertension (OR = 0.065, 95% CI: 0.013-0.317, P = 0.001).

Conclusion:

Individuals with KIR2DS2 and no KIR2DS3 were associated with the increased risk of hypertension. KIR2DS2 that coexisted with KIR2DS3 were associated with the reduced risk of hypertension. Antagonism between KIR2DS2 and KIR2DS3 might serve as a protect factor for hypertension.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Genetic Lingo

Genetic Lingo

Articles linked to this work by shared authors, journal, and citation graph.

Associations of Plasma Deoxycholic Acid and Its Conjugates With the Clinical Outcomes After Ischemic Stroke.

Journal of the American Heart Association·2026

Lactoferrin and zinc sulfate supplementation alleviate cisplatin-induced taste disorder: underlying mechanisms via taste and immune modulation.

NPJ science of food·2026

Laser-Defined Reaction Topology Enables Controllable Solid-State Transformations for Scalable Perovskite Photovoltaics.

Advanced materials (Deerfield Beach, Fla.)·2026

Conformational Elasticity at the Buried Interface: 26.89% Perovskite Solar Cells and 23.95% Certified Modules.

Advanced materials (Deerfield Beach, Fla.)·2026

Serum S100B and Its Interplay With hs-CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke.

Journal of the American Heart Association·2026

Case Report: Dupilumab-associated ulcerative colitis: elucidating the pathomechanistic link between Th2 blockade and Th17 polarized intestinal inflammation.

Frontiers in immunology·2026

See all related articles